SCHEMBL23565871

SCHEMBL23565871

COC(=O)c1ccc(=O)[nH]c1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.51
KDM4E B2RXH2 2/20 0.51
GLA P06280 2/20 0.51
CHEK1 O14757 1/20 0.51
MET P08581 1/20 0.51
GSK3B P49841 1/20 0.51
LIMK1 P53667 1/20 0.51
DYRK1A Q13627 1/20 0.51
CLK4 Q9HAZ1 1/20 0.51
DYRK1B Q9Y463 1/20 0.51
ABL1 P00519 1/20 0.46
NR4A2 P43354 5/20 0.44
PDE3B Q13370 1/20 0.43
PDE3A Q14432 1/20 0.43
MAPT P10636 3/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
PDK2 Q15119 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18395324 0.81 TSHR (0.50) GAAKDM4EPDE3BPDE3AMAPT
SCHEMBL10465981 0.79 KDM4E (0.53) GAAKDM4EGLACHEK1MET
SCHEMBL3929954 0.79 KDM4E (0.53) GAAKDM4EGLACHEK1MET
SCHEMBL18412778 0.79 KMT2A (0.39) KDM4ECHEK1METGSK3BLIMK1
SCHEMBL15797770 0.78 SMN1; SMN2 (0.40) GAAKDM4ECHEK1METGSK3B
SCHEMBL2365705 0.77 CHEK1 (0.48) GAAKDM4EGLACHEK1MET
SCHEMBL391226 0.76 KDM4E (0.50) KDM4EDYRK1ACA12CA9CYP1A2
SCHEMBL31032981 0.74 KDM4E (0.66) GAAKDM4EGLACHEK1MET
SCHEMBL24611913 0.74 HSP90AB1 (0.42) KDM4ECA12CA9TSHRALDH1A1
SCHEMBL1857268 0.74 CHEK1 (0.48) GAAKDM4EGLACHEK1MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114539245-A Pyrimidine-fused ring derivative-containing regulator, and preparation method and application thereof 上海翰森生物医药科技有限公司 2022-05-27 CN disclosed
US-11198681-B2 Heteroaryl inhibitors of PAD4 PADLOCK THERAPEUTICS, INC. (US) 2021-12-14 US disclosed
US-20210188810-A1 HETEROARYL INHIBITORS OF PAD4 PADLOCK THERAPEUTICS INC (US) 2021-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188810-A1 HETEROARYL INHIBITORS OF PAD4 PADI4, PADI1, PADI6 GAA 904/4885KDM4E 117/4885GLA 3805/4885
US-11198681-B2 Heteroaryl inhibitors of PAD4 PADI4, PADI1, PADI6 GAA 904/4885KDM4E 117/4885GLA 3805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.